Enacted: November 2, 2012 / Revised: September 27, 2021
1. Manuscript Submission
Manuscripts for IJGII may be submitted using online ((http://www.ijgii.org/submission). For editorial questions, please contact us via e-mail email@example.com, telephone (+82-2-473-0089), or fax (+82-505-273-0089).
2. Types of Articles
Editorials are invited articles or comments concerning a specific paper in the Journal or a topical issue in the field. Although editorials are normally invited or written by an Editor, unsolicited editorials may be submitted.
Typical length: 2000 words, 40 references.
2.2. Review Articles
These should aim to provide the reader with a balanced overview of an important and topical subject related to gastrointestinal and hepatopancreaticobiliary diseases, and highlight unresolved questions and future directions. Most reviews are solicited by the editors, but unsolicited submissions may also be considered for publication. Section headings should be: Abstract, Introduction, brief main headings, and References.
Typical length: 4000 words, 100 references.
2.3. Original Articles
These may be randomized trials, intervention studies, studies of screening and diagnostic tests, laboratory and animal studies, cohort studies, cost-effectiveness analyses, casecontrol studies, and surveys with high response rates, which represent new and significant contributions to the field. Section headings should be as follows: Abstract, Introduction, Methods, Results, Discussion, Acknowledgments (if applicable), References.
The Introduction section should provide a brief background to the subject of the paper, explain the importance of the study, and state a precise study question or purpose.
The Methods section should describe the study design and methods (including the study setting and dates, patient samples or animal specimens used, inclusion and exclusion criteria, laboratory methods followed, or data sources and how these were selected for the study, essential features of interventions, the main outcome measures), and statistical procedures employed.
Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.
The Results section should comprise the study results presented in a logical sequence, supplemented with tables and/ or figures. The text not repeat data presented in the tables and/or figures.
The Discussion section should be used to emphasize new and important aspects of the study, placing the results in context with published literature, the implications of the findings, and the conclusions that follow from the study results.
Typical length: 3000 words, 80 references.
2.4. Case Reports
These are short discussions of a case or case series with unique features not previously described that make an important teaching point or scientific observation. Section headings should be: Abstract, Introduction, Case Report, Discussion, Acknowledgments (if applicable), References.
The Introduction should describe the purpose of the report, the significance of the disease and its specificity, and briefly review the relevant literature.
Case reports should include the general data of the case, medical history, family history, chief complaint, present illness, clinical manifestation, methods of diagnosis and treatment, and outcome.
The Discussion should compare, analyze and discuss the similarities and differences between the reported case and similar previously reported cases. The importance or specificity of the case should be restated when discussing the differential diagnoses. Suggest the prognosis of the disease and possibility of prevention.
Typical length: 1200 words, 30 references.
2.5. Complication Forums
These are short description of a single case with complication encountered that makes an important teaching point or possibility of prevention. Section headings should be: Abstract, Event Details, Discussion, Prevention, Teaching Point, Acknowledgments (if applicable), References.
Abstract should describe the summary of event and teaching point.
Event Details section should include the general data of the event, medical history, family history, chief complaint, present illness, clinical manifestation, methods of diagnosis and treatment, complications, and patient's outcome.
Prevention section should include how to avoid this complication or what to do differently such as case selection, alternative procedure, different approach, etc.
Teaching point section should include the important point to learn from this complication or possibility of prevention.
Typical length: 1000 words, 10 references, 6 figures.
2.6. Letters to the Editor
These include brief constructive comments concerning previously published articles in the journal. Letters should have a title and include appropriate references, and include the corresponding author's e-mail address. Letters are edited, sometimes extensively, to sharpen their focus. They may be sent for peer review at the discretion of the Editors.
Typical length: 600 words, 5 references; 1 table and/or 1 figure may be included.
3. Manuscript Preparation
3.1. Title Page
The title page should include: category of paper, article title, names of all authors, the institutions with which they are affiliated; indicate all affiliations with a superscripted lowercase number after the author's name and in front of the appropriate affiliation, short running title not exceeding 30 characters, separate word count for abstract and text, and the corresponding author details (name, address, e-mail information, and corresponding author's ORCID number [ORCID, Open Researcher and Contributor ID; https://orcid.org]).
3.2. Abstract and Keywords
An abstract and 3-5 relevant keywords (in alphabetical order) are required for the following article categories: Review Article, Original Article, and Case Report.
Abstracts should be no more than 300 words in length. Abstracts for Original Articles should be structured, with the section headings: Background, Methods, Results, Conclusion. Abstracts for Review Articles and Case Reports are unstructured in one single paragraph. For Case Reports, it should include the significance and purpose of the case presentation, the diagnostic methods of the case, the key data, and brief comments and suggestions with regard to the case.
For selecting keywords, refer to the Index Medicus Medical Subject Headings (National Library of Medicine (US). MeSH [Internet]. Bethesda (MD): National Library of Medicine (US); 1954 [updated 2009, cited 2009 Nov 1]. Available from: https://www.ncbi.nlm.nih.gov/mesh).
3.3. Main Text
The text for Original Articles should include the following sections: Introduction, Materials and Methods, Results, and Discussion. The Introduction should be as concise as possible, without subheadings. The Methods section should be sufficiently detailed. Subheadings may be used to organize the Results and Discussion. Each section should begin on a new page.
Ethics statement should be included in methods section, as the following examples. The study protocol was approved by the institutional review board of #### (IRB No. ##-##-###). Informed consent was confirmed (or waived) by the IRB. The animal studies were performed after receiving approval of the Institutional Animal Care and Use Committee (IACUC) in ### University (IACUC approval No. ##-##-###).
Where a term/definition is 3 times or more in the text, it written in full when it first appears, followed subsequently by the abbreviation in parentheses (even if it was previously defined in the abstract); thereafter, the abbreviation is used.
Current standard international nomenclature for genes should be adhered to. Genes should be typed in italic font and include the accession number. For human genes, use genetic notation and symbols approved by the HUGO Gene Nomenclature Committee (http://www.genenames.org/) or refer to PubMed (https://www.ncbi.nlm.nih.gov/sites/entrez).
Systeme International (SI) units must be used, with the exception of blood pressure values which are to be reported in mmHg. Please use the metric system for the expression of length, area, mass, and volume.
Authors are responsible for the accuracy and completeness of their references and for correct text citation.
3.4.1. In the main text, tables and figure legends
3.4.2. In the references list
Examples are given below.
Standard journal article
Bisdas T, Pichlmaier M, Wilhelmi M, Bisdas S, Haverich A, Teebken O. Effects of the ABO-mismatch between donor and recipient of cryopreserved arterial homografts. Int Angiol. 2011;30:247-55.
Kaplan NM. The endothelium as prognostic factor and therapeutic target: what criteria should we apply? J Cardiovasc Pharmacol. 1998;32(Suppl 3):S78-80.
Journal article not in English but with English abstract
Kawai H, Ishikawa T, Moroi J, Hanyu N, Sawada M, Kobayashi N, et al. Elderly patient with cerebellar malignant astrocytoma. No Shinkei Geka. 2008;36:799-805. [In Japanese, English abstract]
Book with edition
Bradley EL. Medical and surgical management. 2nd ed. Philadelphia: Saunders; 1982, p. 72-95.
Book with editors
Letheridge S, Cannon CR, editors. Bilingual education: teaching English as a second language. New York: Praeger; 1980.
Book chapter in book with editor and edition
Greaves M, Culligan DJ. Blood and bone marrow. In: Underwood JCE, editor. General and systematic pathology. 4th ed. London: Churchill Livingstone; 2004, p. 615-72.
Book series with editors
Wilson JG, Fraser FC, editors. Handbook of teratology, vols. 1-4. New York: Plenum Press; 1977-78.
World Health Organization. World health report 2002: reducing risk, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002.
Duchin JS. Can preparedness for biological terrorism save us from pertussis? Arch Pediatr Adolesc Med. 2004;158.
Available from: http://archpedi.ama-assn.org/cgi/content/full/158/2/106. Accessed June 12, 2004.
Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. Cochrane Database Syst Rev. 2002(2):CD001054. doi:10.1002/14651858.CD1001054.
Item presented at a meeting but not yet published
Khuri FR, Lee JJ, Lippman SM. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. In: Proceedings from the American Society of Clinical Oncology, May 31-June 3, 2003; Chicago, IL. Abstract 359.
Item presented at a meeting and published
Cionni RJ. Color perception in patients with UV- or bluelightfiltering IOLs. In: Symposium on cataract, IOL, and refractive surgery. San Diego, CA: American Society of Cataract and Refractive Surgery; 2004. Abstract 337.
Ayers AJ. Retention of resin restorations by means of enamel etching and by pins [MSD thesis]. Indianapolis: Indiana University; 1971.
American Association of Oral and Maxillofacial Surgeons. Wisdom teeth. AAOMS Website. http://www.aaoms.org/ wisdom_teeth.php. Published 2008. Accessed September 25, 2010.
Eastman Kodak Company, Eastman Organic Chemicals. Catalog no. 49. Rochester, NY: Eastman Kodak; 1977, p. 2-3.
General acknowledgments for consultations, statistical analysis, etc., should be listed after main body of text, before the references, including the names of the individuals involved.
All financial and material support for the research and the work should be stated here clearly explicitly.
Tables are numbered consecutively, in the order of their citation in the text. Table legend example: Table 1 Demographic Characteristics of Patients [note: "Table 1" in bold font without end period; no end period after legend]. Shortening of some words inside table (NOT in table legend): year(s) → yr; month(s) → mo; hour(s) → hr; minute(s) → min; second(s) → sec; and → &. Use en dashes for empty entries. Footnotes are indicated using these symbols (in order of appearance): *, †, ‡, §, ||, ¶, ** [note: when > 10 footnotes, use superscripted lowercase letters]. Abbreviations used in the table, even when already defined in the text, should be defined and placed after the footnotes and presented like in this example: CT, computed tomography; MRI, magnetic resonance imaging. [note: the use of "," with a space on either side, semi-colon to separate, and a period after the last].
Figure legends should be submitted for all figures and should be brief and specific and placed on a separate sheet after the reference section. Figures must be in numerical order using Arabic numerals in the order of their citation in the text. Figures should be uploaded as separate files, not embedded in the manuscript file. Regardless of the application used, when your electronic artwork is finalized, please "save as" or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
Please do not:
Please note that the cost of color illustrations will be charged to the author.
4. Disclosure of Conflicts of Interest
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. Conflict of interest statements will be published at the end of the text of the article, before the 'References' section. Please consult the COPE guidelines (http://www.publicationethics.org/) on conflict of interest. Even when there is no conflict of interest, it should also be stated.
5. Ethical Approval of Studies
For human or animal experimental investigations, appropriate institutional review board or ethics committee approval is required, and such approval should be stated in the methods section of the manuscript. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki (2013) should be followed (World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-researchinvolving-human-subjects/).
6. Redundant Publication or Duplicate Submission
Redundant (or duplicate) publication is publication of a paper that overlaps substantially with one already published in print or electronic media. Submitted manuscripts are considered with the understanding that they have not been published previously in print or electronic format (except in abstract or poster form) and are not under consideration in totality or in part by another publication or electronic medium. For more information, please refer to 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication' (Available at: http://www.icmje.org/recommendations/archives/2008_urm.pdf).
For the policies on the research and publication ethics not stated in this instruction, 'Ethical Policies' section of this Journal can be applied.
7. The Editorial and Peer Review Process
As a general rule, the receipt of a manuscript will be acknowledged within 2 to 4 weeks of submission; authors will be provided with a manuscript reference number for future correspondence. If an acknowledgment is not received in a reasonable period of time, the author should contact the Editorial Office.
Submissions are reviewed by the Editorial Office to ensure that it contains all parts. Submissions will be rejected if the author has not supplied all the material and documents as outlined in these author instructions.
Manuscripts are then reviewed by the Editors, who make an initial assessment. If the manuscript does not appear to be of sufficient merit or is not appropriate for the Journal, the manuscript will be rejected without review. Rejected manuscripts will not be returned to authors unless requested. All other manuscripts are sent to 2 or more expert consultants for double-blind peer review. Authors will usually be notified within 12 weeks of the initial acknowledgment of whether the manuscript is accepted for publication, rejected, or subject to revision before acceptance. However, do note that delays are sometimes unavoidable.
IJGII has a specific process for handling submissions by members of the editorial board to ensure an impartial review, treating the editorial board member as any other author, with no access to the internal editorial process for that submission.
Editorial Interest in Conflict of Interest
Editors who make final decisions about manuscripts must have no personal, professional, or financial involvement in any of the issues they might judge. Other members of the editorial staff, if they participate in editorial decisions, must provide editors with a current description of their financial interests (as they might relate to editorial judgments) and recuse themselves from any decisions in which a conflict of interest exists. Editorial staff must not use information gained through working with manuscripts for private gain. Editors should publish regular disclosure statements about potential conflicts of interests related to the commitments of journal staff. IJGII complies with the Guidelines of the International Committee of Medical Journal Editors on editorial conflict of interest (http://www.icmje.org/#conflicts).
Appeals of an editorial decision
Appeals of a rejection decision are only successful in a handful of cases and usually only when you can provide strong evidence or new data that can respond to and alleviate the concerns of the editor and reviewers. As appeals are matters of journal policy they are given lower priority than new submissions and may take at least several weeks, if not longer, to resolve. Appeals must be rational arguments not emotional ones so be sure you have enough evidence before trying to change the editor's mind.
If you do decide to go ahead with an appeal letter you should:
Clearly explain why you disagree with the decision and provide any new information that you would like the editors to take into consideration. This should not be a repetition of what you have included in your original submission or cover letter.
If the editors or reviewers have highlighted shortcomings with your paper that you think you can address please indicate how you would do this, such as providing further data.
Include a point-by-point response to any reviewer comments.
Provide any evidence to support your opinion when you believe a reviewer has made technical errors in their assessment of your manuscript or has been biased.
Editors will consider one appeal per article and all decisions on appeals are final. The timely review and decision-making process for new submissions will take precedence over appeals.
8. Errata/Retractions Policy
Errata—Errata are corrections to previously published articles. IJGII does not differentiate between errors that originate in the publication process and those that result from errors of scientific logic or methodology.
Expressions of Concern—An expression of concern about the integrity and accuracy of a published article is typically written by an editor, including that phrase in the item title. It is the editor-in-chief's responsibility to initiate appropriate investigative procedures, discover the outcome of the investigation, and notify readers of that outcome in a subsequent issue of IJGII. The outcome may lead to the publication of a retraction notice.
Retractions—Articles may be retracted because of pervasive errors or unsubstantiated or irreproducible data. A partial retraction—when a single paragraph, table, or statement in an article is retracted—may occur if the authors realize that they have drawn the wrong conclusions from their research and wish to subsequently retract those conclusions, even though all of the scientific data reported in an article are sound and valid.
Journal IJGII Policy
This policy applies to all content published in IJGII. The policy was designed to address the need for post-publication corrections, comments, or retractions and to take into account current best practice in scholarly publishing.
As standards evolve and change, IJGII staff will revisit this document. When appropriate, IJGII also publishes letters to the editor (with approval from the editor-in-chief) to allow those with alternative opinions a way to voice them and further the scientific discourse.
The purpose of publishing an erratum, expression of concern, or a retraction is to ensure the integrity of the scientific literature. The following are the policies of IJGII:
9. Similarity Check
Similarity Check is a multi-publisher initiative to screen published and submitted content for originality. To find out more about Similarity Check, visit http://www.crossref.org/crosscheck/index.html. All manuscripts submitted to IJGII may be screened, using the iThenticate tool, for textual similarity to other previously published works.
Published manuscripts are copyrighted to the Society of IJGII, and published under a Creative Commons license. A copyright transfer form should be downloaded in the submission site and submitted to the editorial office by fax or e-mail containing a scanned copyright transfer form on acceptance.
IJGII applies the Creative Commons Attribution License to works it publishes. Under this license, even though the publisher owns the copyright, anyone can download, reuse, reprint, modify, distribute and/or copy the contents.
11. Publication Fees
The publication of article is free of charge, while the authors could be requested to pay actual cost when the special design or reprinting is necessary.
Int J Gastrointest Interv 2020; 9(2): 72-77
Int J Gastrointest Interv 2020; 9(2): 42-52
Int J Gastrointest Interv 2020; 9(3): 99-105
Paul R. Tarnasky, and Prashant Kedia
Gastrointestinal Intervention 2017; 6(1): 37-53
Karel Volenec, and Ivan Pohl
Gastrointestinal Intervention 2016; 5(2): 98-104
Adarsh M. Thaker, and V. Raman Muthusamy
Gastrointestinal Intervention 2017; 6(1): 2-8
© The Society of Gastrointestinal Intervention. Powered by INFOrang Co., Ltd.